FDA approves N-Methanocarbathymidine as orphan drug in U.S

Release Date: 05-Oct-2016

NandN Pharmaceuticals Inc., an upcoming pharmaceuticals company announces N -Methanocarbathymidine receives orphan drug designation for the treatment of neonatal herpes simplex, by FDA.


Almost 25 % of all the pregnant women are seropositive for HSV-2, therefore, 85% of the neonates which are born with HSV-2 infection have one year mortality even with aggressive treatment. Despite of proper treatments the disease may cause death due to presence of virus-associated encephalitis and neutropenia. 


For Orphan Drug Clinical Insight Reports Contact: neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.